As of February 27, 2023, around 77.5 percent of the population in Japan received the second dose of coronavirus disease (COVID-19) vaccination. At the same time, approximately 68.4 percent of the population had a booster shot.

The distribution of COVID-19 vaccination in Japan has begun on February 17, 2021, mainly for health professionals. On April 12, 2021, the government started the vaccine administration for citizens aged 65 and older.

As of February 2023, about 95.8 percent of citizens aged 90 to 99 years in Japan received the third dose of coronavirus disease (COVID-19) vaccinations. The overall share of around 68.4 percent of inhabitants in Japan was vaccinated with the third dose as of the same day.

As of March 16, 2022, close to 79 percent of inhabitants in Akita Prefecture received the second dose of coronavirus disease (COVID-19) vaccination, the highest vaccination rate among all 47 prefectures in Japan. In terms of the booster shot, Yamaguchi Prefecture recorded at around 40.6 percent.

The distribution of COVID-19 vaccination in Japan has begun on February 17, 2021, mainly for health professionals. On April 12, 2021, the government started the vaccine administration for citizens aged 65 and older.

This statistic presents the results of a survey on perceived percentage of infants who receive all the WTO recommended vaccinations in Japan as of October 2018. According to data published by Ipsos, Japanese respondents underestimated the coverage of vaccinations of infants in Japan. On average, the respondents thought that around ** out of every 100 Japanese infants under 12 months have had all the recommended vaccines for diphtheria, tetanus, whooping cough, polio, and measles, when the actual infant vaccination coverage was ** percent in Japan.

Actual value and historical data chart for Japan Immunization Bcg Percent Of One Year Old Children

In 2018, the rate of children vaccinated against diphtheria, tetanus, and pertussis in Japan reached about ** percent, up ***** percentage points from 2015.

Immunization, measles (% of children ages 12-23 months) in Japan was reported at 95 % in 2024, according to the World Bank collection of development indicators, compiled from officially recognized sources. Japan - Immunization, measles (% of children ages 12-23 months) - actual values, historical data, forecasts and projections were sourced from the World Bank on November of 2025.

This study evaluated pneumococcal vaccination status using evaluable data collected from 445 of 1,313 managing directors of elderly care facilities in Japan through an online survey (September 5, 2022-November 25, 2022; UMIN000048747); comparisons were made with the influenza (2021–2022 vaccination only) and coronavirus disease 2019 (COVID-19) vaccination status. Among facilities who kept pneumococcal vaccination records (n = 42), the mean pneumococcal vaccination rate was 31.1%, with the rate being higher for the influenza (93.1%; n = 234) and COVID-19 (94.3%; n = 285) vaccines. Overall, excluding facilities that answered that the corresponding vaccine status at their sites was unknown, the percentage of facilities with high vaccination rates (80% to 100%) was substantially higher for the influenza (80.5%; 351/436) and COVID-19 (89.6%; 396/442) vaccines than for the pneumococcal vaccine (6.5%; 24/370). Multivariable analysis showed that major factors associated with a high pneumococcal vaccination rate (≥15%) were “managing director’s willingness to recommend” and “pneumococcal vaccination request from the residents.” The most common reason for their willingness to recommend the pneumococcal vaccine was that it is an effective disease prevention strategy (83.3%; 65/78) and for their unwillingness to recommend the pneumococcal vaccine was the inability to understand the effectiveness of the vaccine (43.6%; 17/39). In conclusion, there is a need to improve pneumococcal vaccination rates in elderly care facilities in Japan. Strategies such as increasing awareness and encouraging pneumococcal vaccine recommendation among managing directors, especially for residents not eligible for the national subsidy program, and providing regular training on the pneumococcal vaccine for staff and residents are required. Pneumococcal vaccination rates and factors associated with the vaccination of elderly care facility residents are important for policymakers and academia when considering the development and implementation of vaccination programs and guidelines for the management of residents in these facilities. This study evaluated how many elderly people living in care facilities in Japan got pneumococcal vaccine, comparing it with their rates of getting influenza (2021–2022 vaccination only) and COVID-19 vaccines. The information was collected from managing directors of these facilities through an online survey (September 5, 2022-November 25, 2022). Of the 1,313 managing directors contacted, 445 responded. Among the 42 facilities that had recorded pneumococcal vaccination history of their residents, the average vaccination rate was 31.1%, which was much lower than the rates for influenza (93.1%) and COVID-19 (94.3%) vaccines. Only a small percentage of facilities (6.5%) had high (80% to 100%) pneumococcal vaccination rates, while most had high rates for influenza (80.5%) and COVID-19 vaccines (89.6%). Managing directors recommending the pneumococcal vaccine and residents requesting it were major factors in higher vaccination rates. Most managing directors who recommended pneumococcal vaccine believed it was effective, while those who did not recommend often did not understand its effectiveness. In conclusion, there is a need to increase pneumococcal vaccination rates in elderly care facilities in Japan. Strategies such as raising awareness among managing directors, encouraging them to recommend the vaccine (especially for residents not covered by national subsidy programs), and providing regular training on the vaccine to staff and residents are required.

Immunization, DPT (% of children ages 12-23 months) in Japan was reported at 99 % in 2024, according to the World Bank collection of development indicators, compiled from officially recognized sources. Japan - Immunization, DPT (% of children ages 12-23 months) - actual values, historical data, forecasts and projections were sourced from the World Bank on November of 2025.

According to a survey conducted in January 2021, approximately ** percent of surveyed Japanese planned to get a vaccination against the coronavirus (COVID-19). Another around **** percent stated that they decided to get a flu shot after the outbreak of COVID-19. About ** percent of respondents did not plan on getting the COVID-19 vaccine.

Immunization, Pol3 (% of one-year-old children) in Japan was reported at 98 % in 2023, according to the World Bank collection of development indicators, compiled from officially recognized sources. Japan - Immunization, Pol3 (% of one-year-old children) - actual values, historical data, forecasts and projections were sourced from the World Bank on November of 2025.

As of June 7, 2022, China had administered almost 3.4 billion doses of COVID-19 vaccines, representing around 28 percent of the 11.9 billion doses administered worldwide. Vaccination rate China has one of the highest COVID-19 vaccination rates in the world. Nevertheless, the situation varies substantially between age groups. Unlike many other regions such as Japan and western Europe, the Chinese elderly population has a lower vaccination rate than the younger generations. As of March 2022, only around half of people aged above 80 were fully vaccinated in the country, while less than 20 percent had their booster vaccinations. The insufficient vaccination rate among the most vulnerable group of the society partially explains China’s “Zero COVID” strategy, as many fear that the healthcare service will not be able to cope with the spread of COVID-19. Chinese vaccines As a major partner and stakeholder of BioNTech, the German developer of Comirnaty, Chinese pharmaceutical firm Fosun Pharma secured 100 million doses of mRNA COVID-19 vaccines in the early days of the pandemic. Nevertheless, no mRNA vaccine received approval from the Chinese regulator and the majority of the doses secured by Fosun remained undelivered. Sinovac and Sinopharm’s vaccines, the two most common COVID-19 vaccines in China, are both inactivated whole virus vaccines, which stimulate immune responses with killed SARS-CoV-2 virus. Despite having many advantages, they are significantly less effective than mRNA vaccines in preventing symptomatic illness and are especially problematic when encountering the latest Omicron variant of SARS-CoV-2.

As of March 16, 2022, there was a total of approximately 5.9 million confirmed cases of coronavirus disease (COVID-19) in Japan, with around 529 thousand people needing inpatient treatment.

Development of cases in Japan Generally, the increase of new COVID-19 cases recorded from January to March 2020 in Japan followed a slower trajectory as compared to, for example, China, Europe, or the United States of America. The first reported case of COVID-19 in Japan was confirmed on January 16, 2020, when a man that had returned from Wuhan city, China, was tested positive. The first transmission within Japan was recorded on January 28. The number of new cases then increased tenfold in February. April saw a further acceleration of the infection rate. Consequently, the Japanese government declared a nationwide state of emergency that month. The government announced a state of emergency for the second time in January 2021, the third time in April 2021, and the forth time in the July 2021.

Vaccine rollout The Japanese government started the distribution of COVID-19 vaccination in February 2021, mainly for medical professionals. The administration of vaccination for general citizens commenced in April for senior citizens. The vaccine rate of the population was just over 74.7 percent for second doses as of March 2022.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated facts and figure page. 

Recommended routine immunization schedule and percentage of children aged 2–3 years immunized in the 2013 CNIS, China.

According to a survey conducted in October 2024, the majority of Japanese dog owners, more than ** percent, had their pets vaccinated against rabies. Japan is considered a rabies-free country as a consequence of strict preventive measures, with domesticated dogs being required to undergo annual rabies vaccination.

The norovirus forecasting system (NOROCAST) has been developed for predicting directions of changes in genotype proportions between human norovirus (HuNoV) seasons in Japan through modeling herd immunity to structural protein 1 (VP1). Here 404 nearly complete genomic sequences of HuNoV were analyzed to examine whether the performance of NOROCAST could be improved by modeling herd immunity to VP2 and non-structural proteins (NS) in addition to VP1. It was found that the applicability of NOROCAST may be extended by compensating for unavailable sequence data and observed genotype proportions of 0 in each season. Incorporation of herd immunity to VP2 and NS did not appear to improve the performance of NOROCAST, suggesting that VP1 may be a suitable target of vaccines.

This statistic displays the results of a survey asking individuals about their opinion on compulsory vaccinations against serious infectious diseases in Japan in 2018. According to data provided by Ipsos, about ** percent of Japanese respondents stated that vaccinating against serious infectious diseases should be compulsory, while about ten percent disagreed with the idea of compulsory vaccinations.

Number and percentage of individuals with mild/sub clinical dengue infection and those who were hospitalized due to dengue who produced of different cytokines when PBMCs were stimulated DENV-NS3 overlapping peptides and JE Live vaccine.

Proportion of willingness/wait-and-see/unwillingness to be vaccinated by demographic composition: YCS.

According to a survey that was conducted in August 2023 in Japan, over ** percent of women said that they knew about the HPV vaccine. The share was much lower among men.